The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has once again snubbed Translarna ...

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...

Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.